PD Dr. med Karin Hohloch - Davos Sykehus
Det ventes på resultater…
“Neue Radioimmunkonjugate targeting
CD22 (
90Y-epratuzumab tetraxetan)
CD37 (
177Lu-lilotomab satetraxetan)
Anstatt von of CD20 als Epitope für RIT warden derzeit geprüft
Targeting CD22 or CD37 may improve outcome with enhanced delivery and
retention of the radioisotope at the lymphoma site without interfering with
the cold antibody.”